Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications

被引：3

作者：

Saeidi, Hamidreza ^{[1
,6
]}

Bakrin, Ikmal Hisyam ^{[2
]}

Raju, Chandramathi Samudi ^{[3
]}

Ismail, Patimah ^{[1
]}

Saraf, Mohsen ^{[4
,7
]}

Khairul-Asri, Mohd Ghani ^{[5
]}

机构：

[1] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang, Malaysia

[2] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Pathol, Serdang, Malaysia

[3] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia

[4] Univ Isfahan, Fac Engn, Dept Biomed Engn, Esfahan, Iran

[5] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Urol, Serdang, Selangor, Malaysia

[6] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia

[7] Univ Isfahan, Fac Engn, Dept Biomed Engn, Azadi Sq, Esfahan 8174673441, Iran

来源：

ADVANCES IN MEDICAL SCIENCES | 2023年 / 68卷 / 02期

关键词：

Prostate cancer; Homologous recombination repair; Therapeutics; Prognostic; PLATINUM-BASED CHEMOTHERAPY; GERMLINE MUTATIONS; BRCA1; MUTATIONS; RISK; VARIANTS; ATM; MEN; THERAPIES; GENOMICS; OUTCOMES;

D O I：

10.1016/j.advms.2023.09.008

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Prostate cancer (PC) is the second most common cancer in men worldwide. Homologous recombination repair (HRR) gene defects have been identified in a significant proportion of metastatic castration-resistant PC (mCRPC) and are associated with an increased risk of PC and more aggressive PC. Importantly, it has been well-documented that poly ADP-ribose polymerase (PARP) inhibition in cells with HR deficiency (HRD) can cause cell death. This has been exploited for the targeted treatment of PC patients with HRD by PARP inhibitors. Moreover, it has been shown that platinum-based chemotherapy is more effective in mCRPC patients with HRR gene alterations. This review highlights the prognosis and therapeutic implications of HRR gene alterations in PC.

引用

收藏

页码：359 / 365

页数：7

相关论文

共 50 条

[21] Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine [J].

Peters, Cord J. ;

Turner, Clesson E. ;

Chesnut, Gregory T. ;

Giri, Veda N. ;

Gomella, Leonard G. ;

Shriver, Craig D. ;

Dobi, Albert .

CANADIAN JOURNAL OF UROLOGY, 2021, 28 (03) :10659-10667

[22] The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer [J].

Khaddour, Karam ;

Felipe Fernandez, Manuel ;

Khabibov, Marsel ;

Garifullin, Airat ;

Dressler, Danielle ;

Topchu, Iuliia ;

Patel, Jyoti D. ;

Weinberg, Frank ;

Boumber, Yanis .

CANCERS, 2022, 14 (21)

[23] Clinical implications of genetic aberrations in metastatic prostate cancer [J].

Reichert, Zachery R. ;

McKay, Rana R. .

CURRENT OPINION IN UROLOGY, 2019, 29 (04) :319-325

[24] Alterations in homologous recombination repair genes in prostate cancer brain metastases [J].

Rodriguez-Calero, Antonio ;

Gallon, John ;

Akhoundova, Dilara ;

Maletti, Sina ;

Ferguson, Alison ;

Cyrta, Joanna ;

Amstutz, Ursula ;

Garofoli, Andrea ;

Paradiso, Viola ;

Tomlins, Scott A. ;

Hewer, Ekkehard ;

Genitsch, Vera ;

Fleischmann, Achim ;

Vassella, Erik ;

Rushing, Elisabeth J. ;

Grobholz, Rainer ;

Fischer, Ingeborg ;

Jochum, Wolfram ;

Cathomas, Gieri ;

Osunkoya, Adeboye O. ;

Bubendorf, Lukas ;

Moch, Holger ;

Thalmann, George ;

Ng, Charlotte K. Y. ;

Gillessen, Silke ;

Piscuoglio, Salvatore ;

Rubin, Mark A. .

NATURE COMMUNICATIONS, 2022, 13 (01)

[25] Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology [J].

Boussios, Stergios ;

Rassy, Elie ;

Shah, Sidrah ;

Ioannidou, Evangelia ;

Sheriff, Matin ;

Pavlidis, Nicholas .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (05) :329-333

[26] Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes [J].

Olmos, D. ;

Lorente, D. ;

Alameda, D. ;

Cattrini, C. ;

Romero-Laorden, N. ;

Lozano, R. ;

Lopez-Casas, P. P. ;

Jambrina, A. ;

Capone, C. ;

Vanden Broecke, A. M. ;

Trevisan, M. ;

Van Sanden, S. ;

Juergens, A. ;

Herrera-Imbroda, B. ;

Castro, E. .

ANNALS OF ONCOLOGY, 2024, 35 (05) :458-472

[27] Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer [J].

Gonzalez, David ;

Mateo, Joaquin ;

Stenzinger, Albrecht ;

Rojo, Federico ;

Shiller, Michelle ;

Wyatt, Alexander W. ;

Penault-Llorca, Frederique ;

Gomella, Leonard G. ;

Eeles, Ros ;

Bjartell, Anders .

JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2021, 7 (04) :311-325

[28] Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients [J].

Hauke, Ralph J., Jr. ;

Sissung, Tristan M. ;

Figg, William D. .

CANCER BIOLOGY & THERAPY, 2017, 18 (08) :545-546

[29] A transcriptomic model for homologous recombination deficiency in prostate cancer [J].

Weiner, Adam B. ;

Liu, Yang ;

McFarlane, Matthew ;

Bawa, Pushpinder S. ;

Li, Eric, V ;

Zhao, Xin ;

Li, Ziwen ;

Hammoud, Tanya ;

Hazime, Munna ;

Karnes, R. Jeffrey ;

Davicioni, Elai ;

Reichert, Zachery R. ;

Chinnaiyan, Arul M. ;

Lotan, Tamara L. ;

Spratt, Daniel E. ;

Schaeffer, Edward M. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (04) :659-665

[30] Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management [J].

Chen, Mengyu ;

Lei, Ningjing ;

Guo, Ruixia ;

Han, Liping ;

Zhao, Qinghe ;

Zhao, Yang ;

Qiu, Luojie ;

Wu, Fengling ;

Jiang, Shan ;

Tong, Ningyao ;

Wang, Kunmei ;

Li, Siyu ;

Chang, Lei .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16

← 1 2 3 4 5 →